Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04212013 · ClinicalTrials.gov registry record · Phase 3

A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

A Phase 3 study of Marginal Zone Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 3
Development phase
23
Enrollment target
10
Study locations

NCT04212013 is a Phase 3 study of Marginal Zone Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 23 participants, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (77% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04212013, a Phase 3 study of Marginal Zone Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
23 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better.

Conditions Studied

Marginal Zone Lymphoma

Interventions

  • OTHER Placebo
  • DRUG Rituximab
  • DRUG Ibrutinib

Study Locations (10)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

District of Columbia

  • George Washington Cancer Center - Washington D.C.

Florida

  • Moffitt Cancer Center - Tampa

Minnesota

  • Mayo Clinic Cancer Center - Rochester

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2019-12-23
Est. Completion 2027-03-18
Phase Phase 3

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04212013

The ClinicalTrials.gov registry entry for NCT04212013 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 102-participant average among 49 other Marginal Zone Lymphoma trials with a reported enrollment target (77% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Marginal Zone Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04212013 reports 10 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT04212013 about?

NCT04212013 is a clinical study titled "A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma". The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which...

What is the current status of trial NCT04212013?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2019-12-23. Estimated completion is 2027-03-18.

What conditions does trial NCT04212013 study?

This clinical trial studies the following conditions: Marginal Zone Lymphoma.

What interventions are being tested in trial NCT04212013?

The interventions under investigation include: Placebo (OTHER), Rituximab (DRUG), Ibrutinib (DRUG).

Who is sponsoring clinical trial NCT04212013?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04212013 being conducted?

This trial has 10 study locations across District of Columbia, Florida, Minnesota, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Marginal Zone Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Marginal Zone Lymphoma

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.